AI and precision oncology in clinical cancer genomics : from prevention to targeted cancer therapies-an outcomes based patient care

Show simple item record

dc.contributor.author Dlamini, Zodwa
dc.contributor.author Skepu, Amanda
dc.contributor.author Kim, Namkug
dc.contributor.author Mkhabele, Mahlori
dc.contributor.author Khanyile, Richard
dc.contributor.author Molefi, Thulo
dc.contributor.author Mbatha, Sikhumbuzo
dc.contributor.author Setlai, Botle
dc.contributor.author Mulaudzi, Thanyani Victor
dc.contributor.author Mabongo, Mzubanzi
dc.contributor.author Bida, Nndweleni Meshack
dc.contributor.author Kgoebane-Maseko, Minah
dc.contributor.author Mathabe, Kgomotso
dc.contributor.author Lockhat, Zarina I.
dc.contributor.author Kgokolo, C.M.
dc.contributor.author Chauke-Malinga, Nkhensani
dc.contributor.author Ramagaga, Serwalo
dc.contributor.author Hull, Rodney
dc.date.accessioned 2023-08-11T05:52:44Z
dc.date.available 2023-08-11T05:52:44Z
dc.date.issued 2022
dc.description.abstract Precision medicine is the personalization of medicine to suit a specific group of people or even an individual patient, based on genetic or molecular profiling. This can be done using genomic, transcriptomic, epigenomic or proteomic information. Personalized medicine holds great promise, especially in cancer therapy and control, where precision oncology would allow medical practitioners to use this information to optimize the treatment of a patient. Personalized oncology for groups of individuals would also allow for the use of population group specific diagnostic or prognostic biomarkers. Additionally, this information can be used to track the progress of the disease or monitor the response of the patient to treatment. This can be used to establish the molecular basis for drug resistance and allow the targeting of the genes or pathways responsible for drug resistance. Personalized medicine requires the use of large data sets, which must be processed and analysed in order to identify the particular molecular patterns that can inform the decisions required for personalized care. However, the analysis of these large data sets is difficult and time consuming. This is further compounded by the increasing size of these datasets due to technologies such as next generation sequencing (NGS). These difficulties can be met through the use of artificial intelligence (AI) and machine learning (ML). These computational tools use specific neural networks, learning methods, decision making tools and algorithms to construct and improve on models for the analysis of different types of large data sets. These tools can also be used to answer specific questions. Artificial intelligence can also be used to predict the effects of genetic changes on protein structure and therefore function. This review will discuss the current state of the application of AI to omics data, specifically genomic data, and how this is applied to the development of personalized or precision medicine on the treatment of cancer. en_US
dc.description.department Anatomical Pathology en_US
dc.description.department Maxillo-Facial and Oral Surgery en_US
dc.description.department Medical Oncology en_US
dc.description.department Otorhinolaryngology en_US
dc.description.department Radiology en_US
dc.description.department Surgery en_US
dc.description.department Urology en_US
dc.description.librarian hj2023 en_US
dc.description.sponsorship The South African Medical Research Council (SAMRC) and the National Research Foundation (NRF). en_US
dc.description.uri https://www.elsevier.com/locate/imu en_US
dc.identifier.citation Dlamini, Z., Skepu, A., Kim, N. et al. 2022, 'AI and precision oncology in clinical cancer genomics: From prevention to targeted cancer therapies-an outcomes based patient care', Informatics in Medicine Unlocked, vol. 31, art. 100965, pp. 1-12, doi : 10.1016/j.imu.2022.100965. en_US
dc.identifier.issn 2352-9148
dc.identifier.other 10.1016/j.imu.2022.100965
dc.identifier.uri http://hdl.handle.net/2263/91867
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.rights © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). en_US
dc.subject SDG-03: Good health and well-being en_US
dc.subject Precision medicine en_US
dc.subject Precision oncology en_US
dc.subject Cancer therapy and control en_US
dc.subject Personalized oncology en_US
dc.subject Personalized medicine en_US
dc.subject Next-generation sequencing (NGS) en_US
dc.subject Artificial intelligence (AI) en_US
dc.subject Machine learning en_US
dc.title AI and precision oncology in clinical cancer genomics : from prevention to targeted cancer therapies-an outcomes based patient care en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record